NRIX — Nurix Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1549595 ·
Last close
$23.21
Market Cap
$2.41B
52W High
$25.08
52W Low
$14.24
ADV30
1,782,834
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| May 2026 | 9,043,000 | — | -94,204,000 | -89,535,000 | 535,540,000 | 67,685,000 | 132,913,000 |
| Feb 2026 | 6,252,000 | — | -92,495,000 | -87,174,000 | 636,130,000 | 71,195,000 | 155,237,000 |
| Nov 2025 | 13,577,000 | — | -83,095,000 | -78,221,000 | 688,135,000 | 246,960,000 | 149,388,000 |
| Aug 2025 | 7,894,000 | — | -91,385,000 | -86,421,000 | 522,472,000 | 78,438,000 | 150,220,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-293,704,000
Investing CF
$19,992,000
Financing CF
$257,204,000
CapEx
$-10,823,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.45
As of
2026-07-12
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,179,935,000
Inventory
—
Receivables
$19,000,000
ST Investments
$375,844,000
EBIT TTM
$-361,179,000
Pretax Income TTM
$-341,622,000
Interest Exp TTM
—
Analysts
15
Yahoo Snapshot (yfinance, live)
Total Revenue
$36,766,000
EBITDA
$-353,180,000
Free Cash Flow
$-164,635,872
Enterprise Value
$2,061,786,112
Total Cash
$443,528,992
Total Debt
$58,143,000
Shares Out
103,781,683
Trailing EPS
$-3.46
Book Value
$3.88
ROE
-80.3%
ROA
-40.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Nov 2025 | 83,980,000 | -285,666,000 | -264,457,000 | 688,135,000 | 149,388,000 | — | -249,465,000 |
| Nov 2024 | 54,549,000 | -213,027,000 | -193,569,000 | 669,343,000 | 142,350,000 | — | -172,584,000 |
| Nov 2023 | 76,987,000 | -155,063,000 | -143,948,000 | 355,598,000 | 155,105,000 | — | -81,365,000 |
| Nov 2022 | 38,627,000 | -183,867,000 | -180,360,000 | 416,759,000 | 113,063,000 | — | -159,807,000 |
TTM Snapshot
Revenues TTM
$41,846,000
NetIncome TTM
$-131,647,000
OpCashFlow TTM
$0
Assets (Latest)
$669,343,000
Forward EPS
$-1.44
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| NKTR | NEKTAR THERAPEUTICS | $2.39B | $70.67 | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.38B | $50.22 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $2.45B | $24.91 | — |
| VERA | Vera Therapeutics, Inc. | $2.30B | $32.10 | — |
| GIFOF | Grifols SA | $2.29B | $8.85 | — |
News headlines (Yahoo Finance, 1h cache)
Is Kymera Therapeutics Poised for a Breakthrough With KT-621?
2026-07-24 15:18 · Yahoo
Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo
2026-07-21 20:01 · Yahoo
Company News for July 13, 2026
2026-07-13 10:48 · Yahoo
Nurix Therapeutics, Inc. (NRIX) Reports Q2 Loss, Lags Revenue Estimates
2026-07-09 21:25 · Yahoo
Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
2026-07-09 20:01 · Yahoo
Earnings Preview: Nurix Therapeutics, Inc. (NRIX) Q2 Earnings Expected to Decline
2026-07-01 14:00 · Yahoo
Wall Street Analysts Believe Nurix Therapeutics (NRIX) Could Rally 29.23%: Here's is How to Trade
2026-07-01 13:55 · Yahoo
Nurix Therapeutics, Inc. (NRIX) Price Target Raised to $33 on Roche Partnership Value
2026-06-30 13:21 · Yahoo
Nurix Therapeutics (NRIX) Soars 16.4%: Is Further Upside Left in the Stock?
2026-06-26 14:41 · Yahoo
Nurix (NRIX) Climbs to 52-Week High — This Deal May Hold the Answer
2026-06-26 03:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.